A weight-loss pill from Lilly has received US approval, which is expected to lead to increased competition with rival Novo Nordisk. The approval is part of a broader trend of pharmaceutical companies developing obesity treatments, with several outlets suggesting that this year will be significant for the launch of such pills. The market for weight-loss medications appears to be becoming increasingly crowded, with multiple companies, including smaller players, advancing their own products.